Patents by Inventor Abbas ABDOLI

Abbas ABDOLI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors
    Patent number: 12662481
    Abstract: Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.
    Type: Grant
    Filed: January 20, 2022
    Date of Patent: June 23, 2026
    Assignee: Repare Therapeutics Inc.
    Inventors: Sheldon N. Crane, Vouy-linh Truong, Abbas Abdoli, Jean-François Truchon, Cameron Black, Stéphane Dorich, Lee Fader, Stéphanie Lanoix, Paul Jones, Miguel St-Onge, Audrey Picard, Cyrus M. Lacbay
  • HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME
    Publication number: 20250304537
    Abstract: Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.
    Type: Application
    Filed: May 18, 2023
    Publication date: October 2, 2025
    Inventors: Cameron BLACK, Janek SZYCHOWSKI, Bingcan LIU, Evelyne DIETRICH, Frédéric VALLÉE, Simon SURPRENANT, Alexander PERRYMAN, Sheldon N. CRANE, Vouy Linh TRUONG, Alexanne BOUCHARD, Abbas ABDOLI, Frederic IZQUIERDO, Dominique BELLA NDONG, Stephane CIBLAT, Francis BARABE, Thomas PINTER
  • COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS
    Publication number: 20250179070
    Abstract: Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.
    Type: Application
    Filed: February 12, 2025
    Publication date: June 5, 2025
    Inventors: Sheldon N. CRANE, Vouy Linh Truong, Abbas Abdoli, Jean-Francois Truchon, Cameron Black, Stéphanie Dorich, Lee Fader, Stéphanie Lanoix, Paul Jones, Miguel St-Onge, Audrey Picard, Cyrus M. Lacbay
  • Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
    Patent number: 12264155
    Abstract: Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: April 1, 2025
    Assignee: Repare Therapeutics Inc.
    Inventors: Sheldon N. Crane, Vouy Linh Truong, Abbas Abdoli, Jean-François Truchon, Cameron Black, Stéphane Dorich, Lee Fader, Stéphanie Lanoix, Paul Jones, Miguel St-Onge, Audrey Picard, Cyrus M. Lacbay
  • KINASE MODULATORS AND METHODS OF USE THEREOF
    Publication number: 20240174647
    Abstract: The invention provides compounds that modulate the activity of protein kinases that are associated with human diseases, disorders, and conditions. In particular, compounds of the invention inhibit LRRK2.
    Type: Application
    Filed: September 29, 2023
    Publication date: May 30, 2024
    Inventors: Kejia Wu, Abbas Abdoli, Daniel Guay, Abdelkhalek Ben Jamaa, Gyanendra Kumar, Zhonghua Pei, Ryan Simard, Arkadii Vaisburg, Ming Yu
  • QUINAZOLINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME
    Publication number: 20230348456
    Abstract: Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.
    Type: Application
    Filed: April 27, 2023
    Publication date: November 2, 2023
    Applicant: Repare Therapeutics Inc.
    Inventors: Janek SZYCHOWSKI, Bingcan LIU, Evelyne DIETRICH, Alexander PERRYMAN, Sheldon N. CRANE, Vouy Linh TRUONG, Abbas ABDOLI, Alexanne BOUCHARD
  • SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS
    Publication number: 20220185809
    Abstract: Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.
    Type: Application
    Filed: January 20, 2022
    Publication date: June 16, 2022
    Inventors: Sheldon N. Crane, Vouy-linh Truong, Abbas Abdoli, Jean-François Truchon, Cameron Black, Stéphane Dorich, Lee Fader, Stéphanie Lanoix, Paul Jones, Miguel St-Onge, Audrey Picard, Cyrus M. Lacbay
  • COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS
    Publication number: 20210277002
    Abstract: Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.
    Type: Application
    Filed: April 30, 2021
    Publication date: September 9, 2021
    Inventors: Sheldon N. CRANE, Vouy Linh TRUONG, Abbas ABDOLI, Jean-François TRUCHON, Cameron BLACK, Stéphane DORICH, Lee FADER, Stéphanie LANOIX, Paul JONES, Miguel ST-ONGE, Audrey PICARD, Cyrus M. LACBAY